Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

• Published in: The New England journal of medicine Vol. 380; no. 12; pp. 1103 - 1115
• Main Authors: Motzer, Robert J, Penkov, Konstantin, Haanen, John, Rini, Brian, Albiges, Laurence, Campbell, Matthew T, Venugopal, Balaji, Kollmannsberger, Christian, Negrier, Sylvie, Uemura, Motohide, Lee, Jae L, Vasiliev, Aleksandr, Miller, Wilson H, Gurney, Howard, Schmidinger, Manuela, Larkin, James, Atkins, Michael B, Bedke, Jens, Alekseev, Boris, Wang, Jing, Mariani, Mariangela, Robbins, Paul B, Chudnovsky, Aleksander, Fowst, Camilla, Hariharan, Subramanian, Huang, Bo, di Pietro, Alessandra, Choueiri, Toni K
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 21.03.2019
• Subjects: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Axitinib - administration & dosage; Axitinib - adverse effects; Body weight; Cancer therapies; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Drug dosages; Evidence-based medicine; Female; Humans; Immunotherapy; Inhibitor drugs; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kinases; Male; Middle Aged; Monoclonal antibodies; Oncology; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Progression-Free Survival; Renal cell carcinoma; Single-Blind Method; Sunitinib - adverse effects; Sunitinib - therapeutic use; Survival Rate; Targeted cancer therapy; Tumors; Vascular endothelial growth factor; Germany

Among 886 patients with advanced renal-cell cancer, median progression-free survival was 13.8 months among those assigned to avelumab plus axitinib and 7.2 months among those assigned to sunitinib. Toxic effects of grade 3 or higher were similar in the two groups.